Zhenyu Ding-Yu
Chengdu, 610041, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
A novel antituberculosis agent exhibits potent clinical efficacy and good safety profile: an open-label, randomized-controlled, multicenter, phase 2a trial.
Journal: Signal transduction and targeted therapy
Published: July 03, 2025
Risk factors and prognosis of postoperative early relapse after neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma: a retrospective study.
Journal: World journal of surgical oncology
Published: May 27, 2025
Different survival and recurrence patterns between neoadjuvant radiochemotherapy and immunochemotherapy in esophageal squamous cell carcinoma.
Journal: Current problems in surgery
Published: September 05, 2024
Clinical efficacy and immune response of neoadjuvant camrelizumab plus chemotherapy in resectable locally advanced oesophageal squamous cell carcinoma: a phase 2 trial.
Journal: British journal of cancer
Published: April 29, 2024
A dendritic cell vaccine for both vaccination and neoantigen-reactive T cell preparation for cancer immunotherapy in mice.
Journal: Nature communications
Published: December 25, 2023
Zoledronic acid enhances the efficacy of immunotherapy in non-small cell lung cancer.
Journal: International immunopharmacology
Published: May 27, 2022
Increased coexpression of PD-L1 and TIM3/TIGIT is associated with poor overall survival of patients with esophageal squamous cell carcinoma.
Journal: Journal for immunotherapy of cancer
Published: September 17, 2021
Viral infections and the efficacy of PD-(L)1 inhibitors in virus-related cancers: Head and neck squamous cell carcinoma and hepatocellular carcinoma.
Journal: International immunopharmacology
Published: May 13, 2021
Thyroid function abnormality induced by PD-1 inhibitors have a positive impact on survival in patients with non-small cell lung cancer.
Journal: International immunopharmacology
Published: October 17, 2020
Sequential Administration of EGFR-TKI and Pemetrexed Achieved a Long Duration of Response in Advanced NSCLC Patients with EGFR-mutant Tumours.
Journal: Asian Pacific journal of cancer prevention : APJCP
Published: April 01, 2019
Impaired Liver Function Implied Shorter Progression Free Survival for EGFR Tyrosine Kinase Inhibitors
Journal: Asian Pacific journal of cancer prevention : APJCP
Published: August 25, 2018
Last Updated: 09/26/2026